Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-473-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 million
Profitability
Miscellaneous
Employees18
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.02. The biopharmaceutical company earned $0.17 million during the quarter, compared to analysts' expectations of $0.22 million. Geron had a negative return on equity of 19.16% and a negative net margin of 3,077.78%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
4 brokerages have issued 12-month target prices for Geron's shares. Their predictions range from $1.50 to $7.00. On average, they anticipate Geron's share price to reach $3.5750 in the next twelve months. This suggests a possible upside of 228.0% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
News coverage about GERN stock has trended positive on Friday, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Geron earned a news impact score of 2.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term.
Are investors shorting Geron?
Geron saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 35,699,111 shares, an increase of 2.2% from the December 14th total of 36,502,581 shares. Based on an average daily trading volume, of 4,504,534 shares, the days-to-cover ratio is currently 7.9 days. Currently, 19.3% of the company's stock are short sold. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Inflarx (IFRX), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), Epizyme (EPZM), CytomX Therapeutics (CTMX), AC Immune (ACIU), Dynavax Technologies (DVAX), Radius Health (RDUS), ImmunoGen (IMGN), G1 Therapeutics (GTHX), Intra-Cellular Therapies (ITCI), Urogen Pharma (URGN) and Rocket Pharmaceuticals (RCKT).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
- Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
- Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
- Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)
Who are Geron's major shareholders?
Geron's stock is owned by a number of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.10%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which institutional investors are buying Geron stock?
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.09.
How big of a company is Geron?
Geron has a market capitalization of $203.12 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
